Evidence map›Paper›PMID 28282035›Full record

Trial reportBlood cancer journal2017

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

K Suzuki, K Sunami, K Ohashi, S Iida, T Mori, H Handa, K Matsue, M Miyoshi, E Bleickardt, M Matsumoto and 1 more

Abstract readClinical Trial, Phase IIIComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Emerging agents and regimens for multiple myeloma.Journal of hematology & oncology · 2020
    Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

K SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
K SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
K OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
S IidaDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
T MoriDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
H HandaIntegrative Center of Internal Medicine, Division of Hematology, Gunma University Hospital, Gunma, Japan.
K MatsueDepartment of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
M MiyoshiBristol-Myers Squibb K.K, Tokyo, Japan.
E BleickardtOncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ, USA.
M MatsumotoDepartment of Hematology, National Hospital Organisation, Shibukawa Medical Center, Shibukawa, Japan.
M TaniwakiDepartment of Hematology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAsian PeopleDisease-Free SurvivalFemaleHumansJapanMaleMultiple MyelomaSurvival RateAntibodies, Monoclonal, Humanizedelotuzumab

Identifiers

PMID28282035
PMCPMC5380903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.